Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VTAK
Upturn stock ratingUpturn stock rating

Catheter Precision Inc. (VTAK)

Upturn stock ratingUpturn stock rating
$2.92
Last Close (24-hour delay)
Profit since last BUY-11.25%
upturn advisory
Consider higher Upturn Star rating
BUY since 3 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VTAK (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $2

1 Year Target Price $2

Analysts Price Target For last 52 week
$2 Target price
52w Low $2.49
Current$2.92
52w High $47.31

Analysis of Past Performance

Type Stock
Historic Profit -79.75%
Avg. Invested days 12
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.59M USD
Price to earnings Ratio -
1Y Target Price 2
Price to earnings Ratio -
1Y Target Price 2
Volume (30-day avg) 1
Beta -0.28
52 Weeks Range 2.49 - 47.31
Updated Date 08/15/2025
52 Weeks Range 2.49 - 47.31
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 33.63

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Revenue by Geography

Earnings Date

Report Date 2025-08-11
When -
Estimate 0.02
Actual -0.38

Profitability

Profit Margin -
Operating Margin (TTM) -1338.68%

Management Effectiveness

Return on Assets (TTM) -29.44%
Return on Equity (TTM) -184.52%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 70083530
Price to Sales(TTM) 5.98
Enterprise Value 70083530
Price to Sales(TTM) 5.98
Enterprise Value to Revenue 116.81
Enterprise Value to EBITDA 0.27
Shares Outstanding 23300000
Shares Floating 1087840
Shares Outstanding 23300000
Shares Floating 1087840
Percent Insiders 4.31
Percent Institutions 1.78

ai summary icon Upturn AI SWOT

Catheter Precision Inc.

stock logo

Company Overview

overview logo History and Background

Catheter Precision, Inc. was founded in 2011. The company focuses on precision electrophysiology for arrhythmia management. Their key focus is on developing and commercializing innovative technologies for mapping and ablation of cardiac arrhythmias.

business area logo Core Business Areas

  • Mapping and Ablation: Development and commercialization of systems used for mapping and ablation of cardiac arrhythmias. This includes products that aid in visualizing and targeting the areas in the heart causing irregular heartbeats.

leadership logo Leadership and Structure

David Jenkins serves as the Chief Executive Officer. The company has a board of directors overseeing strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • VIVO System: A 3D cardiac mapping system designed to visualize the location and orientation of catheters in the heart during electrophysiological procedures. This helps physicians guide the catheter more accurately and efficiently. No significant market share data available publicly. Competitors include Biosense Webster (JNJ), Abbott (ABT), and Boston Scientific (BSX).
  • LOCAWI System: A catheter tip location system designed to help identify the optimal location to ablate tissue in the heart that causes arrhythmia. No significant market share data available publicly. Competitors include Biosense Webster (JNJ), Abbott (ABT), and Boston Scientific (BSX).

Market Dynamics

industry overview logo Industry Overview

The electrophysiology market is experiencing growth driven by the increasing prevalence of cardiac arrhythmias such as atrial fibrillation. Advancements in technology are driving innovation and adoption of new mapping and ablation techniques.

Positioning

Catheter Precision focuses on developing and marketing innovative mapping and ablation technologies targeting specific niches within the electrophysiology market. Catheter Precision does not appear to hold a large market share.

Total Addressable Market (TAM)

The global electrophysiology market is estimated to be billions of dollars. Catheter Precision is positioned to capture a portion of this TAM through its innovative technologies, however, it is unclear what specific percentage of the TAM they can achieve.

Upturn SWOT Analysis

Strengths

  • Innovative mapping and ablation technologies
  • Focus on precision and accuracy
  • Experienced leadership team

Weaknesses

  • Limited market share
  • Dependence on key products
  • Limited financial resources relative to larger competitors
  • Stock Delisting from NYSE American Exchange

Opportunities

  • Expanding market for electrophysiology procedures
  • Partnerships with larger medical device companies
  • Acquisition by a larger player in the industry
  • FDA Approval of new products.

Threats

  • Competition from larger companies with more resources
  • Technological obsolescence
  • Regulatory hurdles
  • Reimbursement pressures

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • ABT
  • BSX

Competitive Landscape

Catheter Precision faces intense competition from larger, more established companies. Its advantage lies in its innovative technologies. However, its ability to compete effectively depends on securing adequate funding and achieving broader market adoption.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited by market penetration.

Future Projections: Future projections are uncertain and dependent on successful product launches and market adoption.

Recent Initiatives: Recent initiatives focus on commercialization and market expansion efforts.

Summary

Catheter Precision is a small company with innovative technology in the electrophysiology market, but faces significant challenges. It has limited market share and competes against much larger, better-funded companies. The company needs to increase its market presence, secure additional funding, and continue to innovate to remain competitive. The recent delisting also creates concern.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Third-party industry reports
  • Various News Sources

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share and financial data is based on limited available information and estimates.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Catheter Precision Inc.

Exchange NYSE MKT
Headquaters Fort Mill, SC, United States
IPO Launch date 2018-09-27
CEO, Chief Commercial Officer & Executive Chairman Mr. David A. Jenkins
Sector Healthcare
Industry Medical Devices
Full time employees 22
Full time employees 22

Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also offers LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. The company is based in Fort Mill, South Carolina.